Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MGH collaboration to evaluate TRE-515 in ALS patients, advancing development of a first-in-class therapy targeting inflammation and nucleotide metabolism.
-
Name chosen for AVERSA Fentanyl commercial product
-
Sangamo Therapeutics reports recent business highlights and fourth quarter and full year 2025 financial results
-
The neuroprotective agents market in North America is growing at approximately 4.5% CAGR through 2030, with AI-driven approaches.
-
The global market for neuroprotective agents was valued at $41.2 billion in 2024 and is expected to reach $60.9 billion by the end of 2030.
-
Peer-reviewed publication validates the potential of Itay&Beyond's human CNS platform for advanced disease stratification, translational research, and R&D
-
Austin, TX, USA, March 19, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Intracranial Pressure Monitoring Devices Market Size, Trends and Insights By...
-
Austin, TX, USA, March 10, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Viral Vaccine Cell Culture Media Market Size, Trends and Insights By Cell...
-
NEWTOWN, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- CenTrak, a leader in real-time location systems (RTLS) for healthcare, will debut its next generation of products at the HIMSS Global Health...
-
MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...